Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Jun:13:200236.
doi: 10.1016/j.tvr.2022.200236. Epub 2022 May 4.

Human papillomavirus seroprevalence and seroconversion following baseline detection of nine human papillomavirus types in young women

Darron R Brown  1 , Xavier Castellsagué  2 , Daron Ferris  3 , Suzanne M Garland  4 , Warner Huh  5 , Marc Steben  6 , Cosette M Wheeler  7 , Alfred Saah  8 , Alain Luxembourg  8 , Se Li  8 , Christine Velicer  8
Affiliations
Clinical Trial

Human papillomavirus seroprevalence and seroconversion following baseline detection of nine human papillomavirus types in young women

Darron R Brown et al. Tumour Virus Res. 2022 Jun.

Abstract

Background: Estimates of the humoral immune response to incident human papillomavirus (HPV) infections are limited.

Methods: In this post hoc analysis of 3875 women aged 16-23 years from a 4-valent HPV vaccine trial (NCT00092482), HPV seroprevalence on day 1 was measured with a 9-valent HPV (HPV 6/11/16/18/31/33/45/52/58) competitive Luminex immunoassay and compared with cervical/external genital HPV detection by polymerase chain reaction. In the control group, among women who were HPV DNA‒negative on day 1, seroconversion following initial HPV detection was estimated using Kaplan-Meier methods.

Results: Type-specific HPV seropositivity among women with no day 1 cervical/external genital HPV detection was 0.6%-3.6%. Women with any 9-valent HPV (9vHPV) cervical/external genital detection (796/3875; 20.5%) had concordant seropositivity ranging from 13.4% (HPV 45) to 38.5% (HPV 6). Among women in the control group who were negative for all HPV types on day 1, seroconversion by month 30 after initial detection ranged from 29% (HPV 45) to 75% (HPV 16).

Conclusions: Humoral immune response to HPV is variable and dynamic, depending on type-specific exposure. This longitudinal analysis provides insight into the relationship between incident infection and seropositivity.

Clinicaltrials: gov; NCT00092482 https://clinicaltrials.gov/ct2/show/NCT00092482.

Keywords: HPV infection; HPV serology; HPV vaccines; Human papillomavirus; Seroconversion; Seroprevalence.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Serologic sample selection and analyses based on cervical/external genital HPV DNA detection on day 1. Of 3882 subjects enrolled, 3875 subjects received either vaccine or placebo and were included in this analysis. 9vHPV = 9-valent HPV, HPV = human papillomavirus, HR = high-risk, Pap = Papanicolaou.
Fig. 2
Fig. 2
Type-specific HPV seropositivity by cervical/external genital infection status on day 1 among 3875 women 16–23 years old (1788 in placebo group). HPV = human papillomavirus.
Fig. 3
Fig. 3
Proportion of women who seroconverted over time after start of infection containing the same HPV type (placebo group, negative to all tested HPV types on day 1). Seroconversion after any incident infection with (A) HPV 16/18/45 and (B) HPV 31/33/52/58; seroconversion after any incident-persistent infection with (C) HPV 16/18/45 and (D) HPV 31/33/52/58. HPV = human papillomavirus.
See this image and copyright information in PMC

References

    1. Wilson L.E., Pawlita M., Castle P.E., Waterboer T., Sahasrabuddhe V., Gravitt P.E., et al. Natural immune responses against eight oncogenic human papillomaviruses in the ASCUS-LSIL Triage Study. Int. J. Cancer. 2013;133:2172–2181. - PMC - PubMed
    1. Vaccarella S., Franceschi S., Clifford G.M., Touze A., Hsu C.C., de Sanjose S., et al. Seroprevalence of antibodies against human papillomavirus (HPV) types 16 and 18 in four continents: the International Agency for Research on Cancer HPV prevalence Surveys. Cancer Epidemiol. Biomarkers Prev. 2010;19:2379–2388. - PubMed
    1. Carter J.J., Koutsky L.A., Hughes J.P., Lee S.K., Kuypers J., Kiviat N., et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J. Infect. Dis. 2000;181:1911–1919. - PubMed
    1. Wang S.S., Schiffman M., Shields T.S., Herrero R., Hildesheim A., Bratti M.C., et al. Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica. Br. J. Cancer. 2003;89:1248–1254. - PMC - PubMed
    1. Ho G.Y.F., Studentsov Y.Y., Bierman R., Burk R.D. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol. Biomarkers Prev. 2004;13:110–116. - PubMed

Publication types

Substances

Associated data